論文全著者名. 論題. 雑誌名. 発行年; 巻 :始頁-終頁

著者名

Hosoya K, Fujimoto D, Morimoto T, Kumagai T, Tamiya
Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in A, Taniguchi Y, Yokoyama T, Ishida T, Matsumoto H,
PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study. BMC Cancer. 2021 Apr 1;21(1):346. doi: Hirano K, Kominami R, Tomii K, Suzuki H, Hirashima T,
10.1186/s12885-021-08048-4
Tanaka S, Uchida J, Morita M, Kanazu M, Mori M,Nagata K, Fukuda I, Tamiya M

Zenke Y, Tsuboi M, Chiba Y, Tsujino K, Satouchi M,Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non- Sawa K, Shimizu J, Daga H, Fujimoto D, Mori M, Aoki
Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2021 Jun 1;7(6):904-909. doi: T, Sawa T, Omori S, Saka H, Iwamoto Y, Okuno M,Hirashima T, Kashiwabara K, Tachihara M, Ymamoto N,10.1001/jamaoncol.2021.0113. Epub 2021 May 18 PMID: 33734289
Nakagawa KA case report. Thorac Cancer. 2021 Jun;12(12):1935-1939. doi: 10.1111/1759-7714.13948. Epub 2021 May 11

Kuge T, Okabe F, Yamamoto Y, Ishijima M, Uenami T,Kanazu M, Akazawa Y, Yano Y, Yamaguchi T, Mori M.

Bronchial ethanol injection therapy for airway obstruction in lung cancer patients. Respirol Case Rep. 2021 Jul 29;9(9):e0816. doi:
Okabe F, Yano Y, Kuge T, Uenami T, Kanazu M, Mori M
10.1002/rcr2.816. eCollection 2021 Sep.

Saito G, Oya Y, Taniguchi Y, Kawachi H, Daichi F,
Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who
Matsumoto H, Iwasawa S, Suzuki H, Niitsu T, Miyauchi
received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON). Lung Cancer. 2021 Nov;161:86-93. doi:E, Yokoi T, Yokoyama T, Uenami T, Sakata Y, Arai D,
10.1016/j.lungcan.2021.08.019. Epub 2021 Sep 5.
Okada A, Nagata K, Teraoka S, Kokubo M

Tsubata Y, Watanabe K Saito, Nakamura A, Yoshioka
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and H, Morita M, Honda R, Kanaji N, Ohizumi S, Jingu D,
second-generation EGFR-TKI treatments (NEJ032B). Int J Clin Oncol. 2022 Jan;27(1):112-120. doi: 10.1007/s10147-021-02043-2. Epub Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya
2021 Oct 13. PMID: 34643820
N, Akazawa Y, Miura K, Ichihara E, Maemondo M,Morita S, Kobayashi K, Isobe TSakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H,Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T,
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a realSato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda
world setting (OSI-FACT). Eur J Cancer. 2021 Nov 5;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Online ahead of print
H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga
J, Sakagami TTamiya M, Fujikawa K, Suzuki H, Yokoyama T, Uenami
Classification and regression tree for estimating predictive markers to detect T790M mutations after acquired resistance to first line EGFR- T, Tamiya A, Sato Y, Saito G, Uchida J, Morita M,
Hirashima T, Fukuda Y, Kanazu M, Hosoya K, Suzuki T,
TKI: HOPE-002. Invest New Drugs. 2022 Jan 28. doi: 10.1007/s10637-021-01203-5. Online ahead of print
Ueno K, Fujimoto D, Kumagai T, Teramukai S
Fujimoto D, Akamatsu H, Morimoto T, Wakuda K, Sato
Y, Kawa Y, Yokoyama T, Tamiya M, Hiraoka R, Shingu
N, Ikeda H, Tamiya A, Kanazu M, Miyauchi E, Miura S,
Histologic transformation of epidermal growth factor receptor-mutated lung cancer. Eur J Cancer. 2022 Mar 9;166:41-50. doi:
Yanai M, Yomota M, Morinaga R, Yokoi T, Hata A,
10.1016/j.ejca.2022.02.006. Online ahead of print
Suzuki H, Matsumoto H, Sakata S, Furuya N, HarutaniY, Nakachi I, Otsuki A, Uematsu S, Hara S, Yokoo K,Sugimoto T, Yamamoto N
肺癌における個別化医療と分子標的治療．豊中市医師会月報 2021年7月 メディカル・トピックス

森 雅秀